Takumi Fukuchi 1, Hiroshi Nakase, Minoru Matsuura, Takuya Yoshino, Takahiko Toyonaga, Katsuyuki Ohmori, Satoshi Ubukata, Aya Ueda, Takaaki Eguchi, Hiroshi Yamashita, Dai Ito, Kiyoshi Ashida, J Crohns Colitis. 2013 Nov;7(10):803-11.
Tag: cytomegalovirus
Scientific corner
Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus.
Intestinal inflammation might trigger CMV reactivation in a subpopulation of active UC patients without CS treatment. GMAA could be a promising option for active UC positive for CMV.
Scientific corner
Effect and Safety of Granulocyte-Monocyte Adsorption Apheresis for Patients with Ulcerative Colitis Positive for Cytomegalovirus in Comparison with Immunosuppressants.
Takuya Yoshino 1, Hiroshi Nakase, Minoru Matsuura, Kayoko Matsumura, Yusuke Honzawa, Takumi Fukuchi, Kenji Watanabe, Mitsuyuki Murano, Tomoyuki Tsujikawa, Ken Fukunaga, Takayuki Matsumoto, Tsutomu Chiba, Digestion. 2011;84(1):3-9.
The colectomy ratio tends to be high in refractory UC patients with recurrent CMV reactivation or infection. Therefore, GMA might be a safe and effective treatment for UC patients positive for CMV because it does not induce CMV reactivation.
Scientific corner
Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authors’ reply
These new data suggest that GMAA might be safe and effective for UC patients positive for CMV because it does not cause CMV reactivation. Because CMV reactivation might affect the clinical outcome of patients with refractory UC,5 GMAA could be a promising option for UC patients with CMV infection. A new clinical trial with a larger number of patients is ongoing to evaluate further the effects of GMA on UC patients with CMV infection.
Scientific corner
Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection
H. Nakase, M. Matsuura& T. Chiba, doi:10.1111/j.1365-2036.2010.04552.x
These new data suggest that GMAA might be safe and effective for UC patients positive for CMV because it does not cause MV reactivation. Because CMV reactivation might affect the clinical outcome of patients with refractory UC,5 GMAA could be a promising option for UC patients with CMV infection. A new clinical trial with a larger number of patients is ongoing to evaluate further the effects of GMA on UC patients with CMV infection
Contact UsFor more information
Contact Us